6533b863fe1ef96bd12c7d26
RESEARCH PRODUCT
Prediction of leukocyte counts during paediatric acute lymphoblastic leukaemia maintenance therapy
Santeri KarppinenOlli LohiMatti Viholasubject
MaleTime seriesAdolescentaikasarjatNeutrophilsDatasets as Topiclcsh:MedicinebiomarkkeritModels BiologicalArticleMaintenance ChemotherapyPaediatric cancerLeukocyte CountSyöpätaudit - CancersAntineoplastic Combined Chemotherapy ProtocolsLeukocytesHumansDrug Dosage CalculationsChildlcsh:Sciencetilastolliset mallitStochastic modellingstokastiset prosessitStochastic ProcessesvalkosolutMercaptopurinebayesilainen menetelmäStatisticslcsh:RInfantennusteetBayes TheoremPrecursor Cell Lymphoblastic Leukemia-LymphomaApplied mathematicsMethotrexateChild Preschoollääkehoitoakuutti lymfaattinen leukemiasyöpätauditFemalelcsh:Qdescription
Maintenance chemotherapy with oral 6-mercaptopurine and methotrexate remains a cornerstone of modern therapy for acute lymphoblastic leukaemia. The dosage and intensity of therapy are based on surrogate markers such as peripheral blood leukocyte and neutrophil counts. Dosage based leukocyte count predictions could provide support for dosage decisions clinicians face trying to find and maintain an appropriate dosage for the individual patient. We present two Bayesian nonlinear state space models for predicting patient leukocyte counts during the maintenance therapy. The models simplify some aspects of previously proposed models but allow for some extra flexibility. Our second model is an extension which accounts for extra variation in the leukocyte count due to a treatment adversity, infections, using C-reactive protein as a surrogate. The predictive performances of our models are compared against a model from the literature using time series cross-validation with patient data. In our experiments, our simplified models appear more robust and deliver competitive results with the model from the literature. peerReviewed
year | journal | country | edition | language |
---|---|---|---|---|
2019-01-01 |